Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Borja de Miguel"'
Autor:
Rafael San-Juan, Mario Fernández-Ruiz, Francisco López-Medrano, Octavio Carretero, Antonio Lalueza, Guillermo Maestro de la Calle, María Asunción Pérez-Jacoiste Asín, Héctor Bueno, José Manuel Caro-Teller, Mercedes Catalán, Cristina de la Calle, Rocío García-García, Carlos Gómez, Rocío Laguna-Goya, Manuel Lizasoáin, Joaquín Martínez-López, Julia Origüen, Ángel Sevillano, Eduardo Gutiérrez, Borja de Miguel, Fernando Aguilar, Patricia Parra, Mar Ripoll, Tamara Ruiz-Merlo, Hernando Trujillo, José Luis Pablos, Estela Paz-Artal, Carlos Lumbreras, José María Aguado
Publikováno v:
International Journal of Infectious Diseases
International Journal of Infectious Diseases, Vol 117, Iss, Pp 56-64 (2022)
International Journal of Infectious Diseases, Vol 117, Iss, Pp 56-64 (2022)
Background: Controversy remains about the efficacy of tocilizumab (TCZ) for the treatment of severe COVID-19. We aimed to analyze the profile of TCZ-respondent patients. Methods: We retrospectively analyzed a cohort of patients with severe COVID-19 w
Autor:
Estela Paz-Artal, Borja de Miguel, Octavio Carretero, Guillermo Maestro de la Calle, Carlos Mario Gómez Gómez, Mar Ripoll, Rocío García-García, Marcos Sánchez-Fernández, Rafael San Juan, Antonio Lalueza, Carlos Lumbreras, José L. Pablos, José María Aguado, Jaime Lora-Tamayo, Mario Fernández-Ruiz, Joaquin Martinez-Lopez, Cristina de la Calle, Fernando Aguilar, José Manuel Caro-Teller, Angel Sevillano, Julia Origüen, María Asunción Pérez-Jacoiste Asín, Mercedes Catalán, Francisco López-Medrano, Héctor Bueno
Publikováno v:
International Journal of Infectious Diseases, Vol 105, Iss, Pp 319-325 (2021)
International Journal of Infectious Diseases
Repisalud
Instituto de Salud Carlos III (ISCIII)
International Journal of Infectious Diseases
Repisalud
Instituto de Salud Carlos III (ISCIII)
A subgroup of patients with SARS-CoV-2 infection was thought to have developed cytokine release syndrome and were treated with tocilizumab; however, a significant percentage of patients evolved. This study aimed to determine the usefulness of anakinr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::777dcb7922d1a43407a8b1df4cc67853
https://hdl.handle.net/20.500.12105/13431
https://hdl.handle.net/20.500.12105/13431
Autor:
Borja de Miguel-Campo, Fernando Revuelta-Salgado, Eduardo de Miguel-Poch, Isabel Pina-Maiquez, Ricardo García-Luján, Miguel Angel Verdejo-Gómez, Juan Margallo-Iribarnegaray
Publikováno v:
Archivos de Bronconeumología (English Edition). 56:399-401
Autor:
Octavio Carretero, Carlos Lage Gómez, Borja de Miguel, Héctor Bueno, Eduardo Gutiérrez, Joaquin Martinez-Lopez, Julia Origüen, Rafael San Juan, José L. Pablos, Guillermo Chiara-Graciani, José María Aguado, José Tiago Silva, Mercedes Catalán, Hernando Trujillo, Daniel García-Ruiz de Morales, Cristina de la Calle, María Asunción Pérez-Jacoiste Asín, Rocío García-García, Carlos Lumbreras, José Manuel Caro, Antonio Lalueza, Mar Ripoll, Miguel Saro-Buendía, Guillermo Maestro de la Calle, Estela Paz-Artal, Angel Sevillano, Fernando Aguilar, Mario Fernández-Ruiz, Ángel Marrero-Sánchez, Francisco López-Medrano
Publikováno v:
International Journal of Infectious Diseases
International Journal of Infectious Diseases, Vol 105, Iss, Pp 487-494 (2021)
International Journal of Infectious Diseases, Vol 105, Iss, Pp 487-494 (2021)
BackgroundThe role of combination immunomodulatory therapy with systemic corticosteroids and tocilizumab (TCZ) for aged patients with COVID-19-associated cytokine release syndrome remains unclear.MethodsWe conducted a retrospective single-center stud
Autor:
Carlos Lumbreras, Jaime Lora-Tamayo, Irene Losada, Octavio Carretero, José María Aguado, Rafael San Juan, Mikel Mancheño-Losa, Estibaliz Arrieta, Antonio Lalueza, A. García-Reyne, Guillermo Maestro de la Calle, Mario Fernández-Ruiz, Cristina de la Calle, Raquel Díaz-Simón, Borja de Miguel, Francisco López-Medrano
Publikováno v:
European Journal of Clinical Microbiology & Infectious Diseases
The aim of our study was to elucidate if SARS-CoV-2 viral load on admission, measured by real-time reverse transcriptase–polymerase chain reaction (rRT-PCR) cycle threshold (Ct) value on nasopharyngeal samples, was a marker of disease severity. All